Kyprolis

Carfilzomib, the active ingredient in Kyprolis, is a proteasome inhibitor presented as an injectable solution for intravenous use. It is indicated for the treatment of relapsed or refractory multiple myeloma in adult patients who have received prior therapy.

GNH USA supplies Kyprolis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring product integrity through stringent quality controls and appropriate cold‑chain logistics. The company adheres to EU GMP standards and provides regulatory documentation to facilitate import and clinical use.

Kyprolis (carfilzomib) is employed in the treatment of multiple myeloma, a hematologic cancer, either alone or in combination with other agents.

- Multiple myeloma (relapsed or refractory) – monotherapy: Provides disease control and extends progression‑free survival in patients who have received prior therapies. - Multiple myeloma (relapsed or refractory) – in combination with lenalidomide and dexamethasone: Enhances overall response rates and depth of remission. - Multiple myeloma (newly diagnosed) – in combination with lenalidomide and dexamethasone: Used as part of frontline therapy to achieve higher response rates.

Carfilzomib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: Persistent tiredness affecting daily activities. - Nausea: Mild to moderate upset stomach. - Anemia: Reduced red blood cell count leading to weakness. - Thrombocytopenia: Low platelet levels increasing bleeding risk. - Dyspnea: Shortness of breath during exertion. - Peripheral edema: Swelling of extremities.

Serious or Rare Side Effects: - Cardiac failure: Decreased heart function that may require hospitalization. - Pulmonary hypertension: Elevated pressure in lung arteries causing breathlessness. - Severe infusion reactions: Acute hypersensitivity with hypotension or rash. - Tumor lysis syndrome: Rapid tumor cell breakdown causing metabolic disturbances. - Renal failure: Impaired kidney function requiring dialysis. - Severe infections: Opportunistic infections requiring antimicrobial therapy.

When using Kyprolis, clinicians should observe specific safety measures to minimize risks.

- Cardiac monitoring: Assess baseline and periodic left ventricular function due to risk of heart failure. - Pulmonary assessment: Evaluate for signs of pulmonary hypertension before and during therapy. - Hematologic surveillance: Perform regular complete blood counts to detect anemia, thrombocytopenia, or neutropenia. - Renal function evaluation: Adjust dosing or discontinue in patients with significant renal impairment. - Pregnancy avoidance: Contraindicated in pregnancy (Category D); ensure effective contraception for women of childbearing potential. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Carfilzomib may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): Can markedly increase carfilzomib exposure and toxicity. - Co‑administration with other proteasome inhibitors: May lead to overlapping toxicities. - QT‑prolonging agents: Heightened risk of cardiac arrhythmias. - Concurrent cardiotoxic drugs (e.g., anthracyclines): Exacerbates cardiac adverse events. - Live vaccines: Immunosuppression may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): May modestly raise carfilzomib levels. - Antifungal azoles: Require close monitoring of cardiac and hematologic parameters. - Antihypertensives: Adjust doses as blood pressure may fluctuate. - Diuretics: Potential impact on fluid balance and renal function. - Anticoagulants: Increased bleeding risk due to thrombocytopenia.